Valuation: Lin BioScience, Inc.

Market Cap	57.65B 1.79B 1.54B 1.44B 1.32B 2.49B 170B 2.53B 16.92B 6.64B 85.15B 6.7B 6.56B 282B	P/E 2024	-14.5x	P/E 2025	-23.9x
Enterprise Value	41.38B 1.28B 1.11B 1.03B 949M 1.79B 122B 1.81B 12.14B 4.77B 61.12B 4.81B 4.71B 202B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : Lin BioScience, Inc.

04-28	Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-26	Catalytic Transition Fund, managed by Brookfield Asset Management Ltd. acquired Alba Renewables Pte. Ltd. from SUSI Asia Energy Transition Fund Scsp, managed by SUSI Partners AG.	CI
25-09-10	Gateway Partners Limited and Leafgreen Capital Pte Ltd acquired Demeter Indo Investment Pte. Ltd. from KKR & Co. Inc..	CI
25-08-13	Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-04-30	Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-08-13	Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-04-23	Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-08-14	Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-04-25	Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-08-12	Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
22-04-24	Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
21-08-13	Lin Bioscience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	CI
21-05-06	Lin Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI

More news

Press Releases: Lin BioScience, Inc.

24-11-27

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

More press releases

Managers and Directors: Lin BioScience, Inc.

Manager	Title	Age	Since
Cheng Chi Wang CEO	Chief Executive Officer	-	2016-05-31
Wan Shan Chen DFI	Director of Finance/CFO	40	2022-07-24
Hung Wei Chen COO	Chief Operating Officer	45	2018-07-31

Director	Title	Age	Since
Yue Hsin Lin CHM	Chairman	48	2016-10-12
Cheng Chi Wang BRD	Director/Board Member	-	2024-06-26
Hui Chun Wang BRD	Director/Board Member	80	2018-09-26

More insiders

LIN BIOSCIENCE, INC. is a Taiwan-based company mainly engaged in the development of new pharmaceutical drugs. The Company is in the research and development and clinical trials stage. It has four major drugs in development, including LBS-008, LBS-007, LBS-009 and LBS-002, as well as two technical platforms of RBP4 and CDC7. LBS-008 is developed for dry macular degeneration which belongs to the best-selling drugs, and stel lesions which belongs to orphan drugs. LBS-007 is used in acute leukemia which belongs to orphan drugs, and solid tumors which belongs to the best-selling drugs. LBS-009 is used in non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and type 2 diabetes. LBS-002 is developed for primary brain cancer and metastatic brain cancer. RBP4 platform is used for metabolic diseases, and CDC7 platform is used for all cancers.

Employees

Sector

Pharmaceuticals

Calendar

08-31 Significant Split/Dividend

More about the company

Quotes

Date	Price	Change	Volume
26-08-07	NT$696.00	-5.18%	1,334,478
26-08-06	NT$734.00	+4.26%	2,477,847
26-08-05	NT$704.00	+2.77%	926,828
26-08-04	NT$685.00	-1.58%	537,670
26-08-03	NT$696.00	+2.20%	804,501

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Taipei Exchange Other stock markets 2026-08-07			5-day change	1st Jan Change
696.00 ^TWD	-5.18%		+2.20%	+75.31%

1 day	-5.18%
1 week	+2.20%
Current month	+2.20%
1 month	+7.41%
3 months	+77.10%
6 months	+74.22%
Current year	+75.31%

1 week	660	768
1 month	520	773
Current year	331	773
1 year	149	773
3 years	70	773
5 years	70	773
10 years	27	773

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LIN BIOSCIENCE, INC.	-5.18%	+2.20%	+329.63%	+477.59%	1.79B
ELI LILLY AND COMPANY	-0.52%	+3.21%	+89.52%	+127.32%	1,057B
JOHNSON & JOHNSON	+0.88%	+1.13%	+49.56%	+49.69%	625B
ABBVIE INC.	+0.89%	-1.95%	+24.23%	+64.44%	435B
ROCHE HOLDING AG	+0.71%	+3.87%	+49.07%	+37.85%	363B
NOVARTIS AG	+0.64%	-0.49%	+33.94%	+40.01%	296B
ASTRAZENECA PLC	+0.39%	-5.83%	+8.92%	+7.85%	249B
AMGEN INC.	+1.51%	+6.69%	+42.58%	+57.57%	222B
NOVO NORDISK A/S	+3.92%	-0.46%	-5.56%	-52.32%	209B
GILEAD SCIENCES, INC.	+1.80%	+2.30%	+11.56%	+66.35%	165B
Average	+0.50%	+0.78%	+63.34%	+87.64%	362.26B
Weighted average by Cap.	+0.66%	+1.22%	+48.86%	+64.84%

	2024	2025
Net sales	-	-
Net income	-744M -23.05M -19.94M -18.62M -17.08M -32.12M -2.19B -32.63M -218M -85.73M -1.1B -86.54M -84.65M -3.63B	-1.36B -42.2M -36.5M -34.09M -31.27M -58.82M -4.02B -59.75M -400M -157M -2.01B -158M -155M -6.66B
Net Debt	-5.17B -160M -139M -129M -119M -223M -15.25B -227M -1.52B -596M -7.64B -602M -589M -25.27B	-16.27B -504M -436M -407M -373M -702M -47.95B -713M -4.77B -1.87B -24.03B -1.89B -1.85B -79.45B

Lin BioScience, Inc. Stock

Stocks

6696

TW0006696008

Pharmaceuticals

Valuation: Lin BioScience, Inc.

Chart: Lin BioScience, Inc.

Latest news : Lin BioScience, Inc.

Press Releases: Lin BioScience, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Lin BioScience, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates